SEARCH:   Advanced

Blood, 15 October 2007, Vol. 110, No. 8, pp. 2811-2818. Prepublished online as a Blood First Edition Paper on July 16, 2007; DOI 10.1182/blood-2007-01-068932. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-01-068932v1 110/8/2811    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kater, A. P. Articles by Kipps, T. J. Search for Related Content PubMed PubMed Citation Articles by Kater, A. P. Articles by Kipps, T. J. Related Collections Neoplasia Immunotherapy Reviews in Translational Hematology Review Articles Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  REVIEW ARTICLE Cellular immune therapy for chronic lymphocytic leukemia Arnon P. Kater1, Marinus H. J. van Oers1, and Thomas J. Kipps2 1 Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands; and 2 Moores Cancer Center at the University of California, San Diego, CA Although chemotherapy can induce complete responses in patients with chronic lymphocytic leukemia (CLL), it is not considered curative. Treated patients generally develop recurrent disease requiring additional therapy, which can cause worsening immune dysfunction, myelosuppression, and selection for chemotherapy-resistant leukemia-cell subclones. Cellular immune therapy promises to mitigate these complications and potentially provide for curative treatment. Most experience with this is in the use of allogeneic hematopoietic stem-cell transplantation (allo-HSCT), in which graft-versus-leukemia (GVL) effects can be observed and shown responsible for long-term disease-free survival. However, use of allo-HSCT for CLL is limited because of the lack of suitable donors and the treatment-related morbidity/mortality for elderly patients, who constitute the majority at risk for developing this disease. The GVL effect, however, suggests there are specific CLL-associated antigens that could be targeted in autologous cellular immune therapy. Effective strategies for this will have to overcome the disease-related acquired immune deficiency and the capacity of the leukemia-cell to induce T-cell tolerance, thereby compromising the activity of even conventional vaccines in patients with this disease. We will discuss the different strategies being developed to overcome these limitations that might provide for effective cellular immune therapy of CLL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. G. Ramsay and J. G. Gribben Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug Haematologica, September 1, 2009; 94(9): 1198 - 1202. [Full Text] [PDF] G. Gorgun, A. G. Ramsay, T. A. W. Holderried, D. Zahrieh, R. Le Dieu, F. Liu, J. Quackenbush, C. M. Croce, and J. G. Gribben E{micro}-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction PNAS, April 14, 2009; 106(15): 6250 - 6255. [Abstract] [Full Text] [PDF] T. Fukuda, L. Chen, T. Endo, L. Tang, D. Lu, J. E. Castro, G. F. Widhopf II, L. Z. Rassenti, M. J. Cantwell, C. E. Prussak, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a PNAS, February 26, 2008; 105(8): 3047 - 3052. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020